Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Pfizer Inc. Add to portfolio

NYA:PFE, Feb 21, 09:01 UTC

Latest NYA:PFE News

Filter your feed

Apply Filter

Wednesday, February 12


News

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

PFE

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study. Pfizer Inc. PFE and Japanese partner Astellas announced overall survival (OS) data from a late-stage study evaluating the combo of Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with non-metastatic castration-resistant prostate cancer (nmCRPC). We remind investors that in July 2018, the FDA granted approval to Xtandi for treating the non-metastatic CRPC patient population based on metastasis-free survival (MFS) data from the PROSPER study. The label expansion of Xtandi allows it to treat a broader prostate cancer patient population and drive growth for Pfizer. However, the medicine faces competition from Johnson & Johnson’s JNJ new prostate cancer drug Erleada and the generic versions of its product Zytiga.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, February 11


News

Better Buy: Pfizer vs. AbbVie

PFE ABBV

Pfizer(NYSE: PFE) and AbbVie(NYSE: ABBV) are both top-notch dividend stocks. Nonetheless, these two elite income stocks have been headed in drastically different directions over the past half-year. While AbbVie's shares have produced total returns on capital of 48% (when including dividends) over the last six months, Pfizer's stock has generated a far more modest return on capital of only 6% during the same period. The central issue behind this stark divergence is that Pfizer and AbbVie have taken markedly different approaches toward solving the same problem: namely, the loss of exclusivity for key revenue generators. Pfizer's new lineup of growth products, which includes Ibrance, Xtandi, Eliquis, Xeljanz, and Vyndaqel, should be sufficient to effectively close this dark chapter in the company's history. But there is a major element of the unknown with Pfizer at the moment.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Financial

Thursday, February 06


News

Should Investors Buy Pfizer on the Dip?

PFE

Pfizer (NYSE: PFE) still hasn't recovered from the fall the stock took back in late July, when analysts downgraded the stock after a disappointing earnings result and forecast, affected by the company's decision to exit its Upjohn business. Although the stock has been rallying in the months since then, over the past six months, it's up just 4% and nowhere near the S&P 500's returns of 16% during that time. Pfizer has also been struggling in recent days as it released its fourth-quarter results on Jan. 28, which didn't inspire much enthusiasm from investors. However, let's take a look at whether the underperforming stock is likely to rally, or if more red is in its future. It disappointed investors in Q4, with sales down from the prior-year quarter while earnings missed expectations. However, the company did indicate that it expects the new-look Pfizer to achieve operational revenue growth of 8% for 2020. Over the longer term, spinning off the Upjohn business, which features off-patent medicine, could be a way for Pfizer to focus on higher-growth products that can generate more revenue for the company. However, it's still unclear how all of that will pan out and just how much additional growth the company will generate. For now, it looks as though investors need some convincing of that given their lack of enthusiasm thus far.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Health
  • Financial

Tuesday, February 04


News

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

PG PFE +3 more PG PFE AMZN HUM LUV

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Looking at Q4 as a whole, combining the actual results that have come out with estimates for the still-to-come companies, total earnings are expected to be down -0.6% from the same period last year on +4% higher revenues. The Zacks analyst believes that the company’s solid second-quarter fiscal 2020 earnings mark the continuation of its positive surprise trend. Pfizer’s shares have underperformed the Zacks Large Cap Pharmaceuticals over the past two-year period (+7.4% vs. +17.9%). But the Zacks analyst believes that the company’s Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Read Full Details

Topics:
  • Business
  • Financial

Friday, January 31


News

Pfizer's Biosimilar Ruxience Gets EU Regulatory Backing

PFE

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended that the European Commission approve Pfizer's (NYSE: PFE) drug Ruxience, a biosimilar to MabThera, which to Roche(OTC: RHHBY) and Biogen(NASDAQ: BIIB) sell in the U.S. as Rituxan. This difference in how they're manufactured means that while another company may be able to develop a biologic that does essentially the same thing as a previously approved drug, that new version -- the biosimilar -- will not be not quite the same as the original -- thus the "similar" in the name. Image source: Getty Images. While Pfizer is better known for its branded drugs, the pharmaceutical company has jumped on the biosimilar bandwagon; it has already developed four other oncology biosimilars that are available in Europe. Pfizer has also gotten a taste of its own medicine on this front: Sales of its anti-inflammatory biologic Enbrel were down 18% in the fourth quarter due to biosimilar competition. When Pfizer hives off its Upjohn generic drug unit later this year, its biosimilars will stay with the branded drug division.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

5 Reasons Pfizer Is Big Pharma's Top Dividend Stock to Buy Right Now

PFE

Pfizer(NYSE: PFE) recently reported fourth-quarter earnings that missed expectations on the top and bottom line. As a result, a jumpy stock market knocked a few percentage points off the stock price. Despite missing consensus forecasts, Pfizer stock looks like a perfect fit for dividend portfolios. The average stock in the S&P 500 trades at 19.3 times forward estimates at the moment. Since announcing fourth-quarter earnings, shares of Pfizer have fallen to just 13.7 times the low end of the company's 2020 adjusted earnings forecast. Rapid growth from the Pfizer that remains. While Viatris delivers a dividend powered by fairly steady profits, the company that remains could deliver a payout that grows at a hair-raising pace for years to come.

Read Full Details

Story Sources

nasdaq.com fool.com
Topics:
  • Business
  • Financial

Thursday, January 30


News

United States' $9 Billion Pneumonia Vaccine Industry, 2020-2026 - Major Players are Merck, Pfizer, GlaxoSmithKline (GSK), LG Chem, and SK Chemical (Sanofi Pasteur)

PFE GSK

Key trends in terms of collaboration deals, licensing agreement and partnership deals are analysed with details. The report also examines the main market growth driving and restraining forces and also gives an all-round future outlook through 2026.The report also provides comprehensive profiles of the dominant players in the country's pneumonia vaccines market such as Pfizer and Merck with important details on companies' vaccines portfolio and the latest developments. Other emerging players such as GlaxoSmithKline (GSK), LG Chem, and SK Chemical (Sanofi Pasteur) are making novel technology-based pneumonia vaccines that are likely to affect the market share during the forecast period.The Major Companies Dominating this Market for its Products, Services, and Continuous Product Developments are:. United States Pneumonia Vaccines Market Assessment & Opportunity (Value), 2015 - 20263.1 Prevnar / Prevnar 133.2 Pneumovax 233.3 V1143.4 PF-064820773.5 GSK34.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Triple-Negative Breast Cancer Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Novartis AG, Eisai Co Ltd & Bayer AG - ResearchAndMarkets.com

PFE BAYN

This report provides top line data relating to the clinical trials on Triple-Negative Breast Cancer (TNBC) Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Alzheimer's Disease Global Clinical Trials Review, H2, 2019 - Pfizer Inc, Eisai Co Ltd, Allergan Plc & The Lundbeck Foundation - ResearchAndMarkets.com

PFE AGN

This report provides top line data relating to the clinical trials on Alzheimer's DiseaseReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status. Nov 20, 2019: Athira Pharma to present phase 1 data for NDX-1017 in oral presentation at 2019 clinical trials on Alzheimer's Disease (CTAD) Conference.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd - ResearchAndMarkets.com

BHC PFE +2 more BHC PFE AGN OR

Global Wrinkles Clinical Trials Review, H2 2019 - Allergan Plc, Bausch Health Companies Inc, L'Oreal SA & Huons Global Co Ltd - ResearchAndMarkets.com. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial